RxDoctor Payments Data

Leticia Tornes, MD

Neurology · Miami, FLNPI 1922201623

Payments from drug & device makers

$216,595in general payments, 2019–2025

Across 109 payments — averaging $1987.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Adamas Pharmaceuticals, Inc.$117K
  • AstraZeneca$50K
  • Genentech, Inc.$41K
  • Biogen$8K
  • EMD Serono, Inc.$393
  • Novartis$294
  • plus $553 from 11 others

What the payments were for

  • Consulting fees$7,05065%
  • Travel & lodging$1,19611%
  • Food & beverage$2,57024%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$216,595 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$7,394
Medicare patients
30
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab23$198,789
VumerityDiroximel Fumarate12$101,345
Clobazam30$8,263
Dalfampridine ErDalfampridine28$5,865
VyvanseLisdexamfetamine Dimesylate12$4,864
Rufinamide13$2,985
Levetiracetam48$2,781
Clorazepate Dipotassium19$2,709
Carbamazepine ErCarbamazepine13$2,364
Lacosamide24$1,268
Modafinil17$1,088
Oxcarbazepine13$935
Divalproex Sodium33$920
Baclofen47$898
Gabapentin59$837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$7,623$101,34512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →